Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
Part of paid clinical trials in Birmingham, Alabama.
- Sponsor
- Pharvaris Netherlands B.V.
- Study ID
- NCT06679881
- Phase
- PHASE3
- Status
- Recruiting
Conditions
- Hereditary Angioedema (HAE)
Eligibility Criteria
- Sex
- ALL
- Age
- 12 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Deucrictibant — DRUGDeucrictibant extended-release tablet for once daily oral use
Study Details
This is a Phase 3, multicenter, long-term, open-label study to evaluate the safety and efficacy of once-daily orally administered deucrictibant extended-release tablet for prophylaxis to prevent angioedema attacks in participants aged ≥12 years with Hereditary Angioedema
Key Dates
- Start date
- Feb 1, 2025
- Status verified
- May 2026
- Primary completion
- Dec 31, 2028
- Completion
- Dec 31, 2028
Study Design
- Enrollment
- 170 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: DeucrictibantDeucrictibant
Primary Outcome Measure
Treatment-emergent adverse events (TEAEs), including serious adverse events (SAEs), adverse events of special interest (AESIs), and TEAEs leading to study drug discontinuation [ Time Frame: 130 weeks ]
Central Contacts
- Pharvaris Clinical Team0031 712-036-410
Locations (12)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Study Site | Birmingham | Alabama | 35209 | - |
| Study Site | Scottsdale | Arizona | 85251 | - |
| Study Site | Little Rock | Arkansas | 72205 | - |
| Study Site | San Diego | California | 92122 | - |
| Study Site | Santa Monica | California | 90404 | - |
| Study Site | Walnut Creek | California | 94598 | - |
| Study Site | Wheaton | Maryland | 20902 | - |
| Study Site | St Louis | Missouri | 63141 | - |
| Study Site | Las Vegas | Nevada | 89128-0450 | - |
| Study Site | Hershey | Pennsylvania | 17033 | - |
| Study Site | Dallas | Texas | 75231 | - |
| Study Site | Milwaukee | Wisconsin | 53226-3067 | - |
Find similar trials in Birmingham, AL
Related Studies
- Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary AngioedemaPHASE2/PHASE3 · Enrolling By Invitation · Pharvaris Netherlands B.V. · Birmingham, Alabama
- A Study of Navenibart in Participants With Hereditary AngioedemaPHASE3 · Enrolling By Invitation · Astria Therapeutics, Inc. · Birmingham, Alabama
- Oral Deucrictibant for Prophylactic and Acute Treatment in Hereditary Angioedema PatientsPHASE1/PHASE2 · Recruiting · Institute for Asthma and Allergy · Wheaton, Maryland
- A Long-Term Study of Navenibart in Participants With Hereditary AngioedemaPHASE3 · Enrolling By Invitation · Astria Therapeutics, Inc. · Scottsdale, Arizona